UNIRAD UK Sample collection
Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease (UNIRAD).
- Malignant tumour of breast
15 Cotswold Road
|Year||Access Requests Received||Access Requests Approved|